We collaborated with WIRED by helping connect patients willing to share their experiences as compounded GLP-1 access came to an abrupt end. Their stories illustrated the human cost of shifting FDA policy, insurance denials, and manufacturer pricing, showing how quickly patients can be left scrambling when affordable alternatives are taken away. By grounding the article in real-world patient voices, we helped highlight the urgency of sustainable, affordable GLP-1 access and the risks patients face when forced into unstable or unsafe options.
This newsletter is owned and produced by GLP-1 Studio LLC, a separate for-profit platform that shares updates in support of the GLP-1 Collective nonprofit.
Subscriptions are optional, free unless you choose paid, and not tax-deductible.
